Among these TKIs, only sorafenib resistance possesses a comprehensive in vitro and clinical evaluation, which is provided by the work of Tong et al. In this study, ANXA3 overexpression was detected in sorafenib-resistant HepG2 and Huh7 hepatocellular carcinoma cells as well as in patient-derived xenografts; conversely, inhibition of ANXA3 achieved with shANXA3 re-sensitized the response to sorafenib in vitro and limited tumor growth in vivo (Tong et al., 2018). The gene discussed is ANXA3; the disease is neoplasm.